Literature DB >> 17513732

CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.

Kutlu G Elpek1, Chantale Lacelle, Narendra P Singh, Esma S Yolcu, Haval Shirwan.   

Abstract

Tumors use a complex set of direct and indirect mechanisms to evade the immune system. Naturally arising CD4(+)CD25(+)FoxP3(+) T regulatory (Treg) cells have been implicated recently in tumor immune escape mechanism, but the relative contribution of these cells to overall tumor progression compared with other immune evasion mechanisms remains to be elucidated. Using the A20 B cell lymphoma as a transplantable tumor model, we demonstrate that this tumor employs multiple direct (expression of immunoinhibitory molecule PD-L1, IDO, and IL-10, and lack of expression of CD80 costimulatory molecule) and indirect (down-regulation of APC function and induction of Treg cells) immune evasion mechanisms. Importantly, Treg cells served as the dominant immune escape mechanism early in tumor progression because the physical elimination of these cells before tumor challenge resulted in tumor-free survival in 70% of mice, whereas their depletion in animals with established tumors had no therapeutic effect. Therefore, our data suggest that Treg cells may serve as an important therapeutic target for patients with early stages of cancer and that more vigorous combinatorial approaches simultaneously targeting multiple immune evasion as well as immunosurveillance mechanisms for the generation of a productive immune response against tumor may be required for effective immunotherapy in patients with advanced disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17513732     DOI: 10.4049/jimmunol.178.11.6840

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

3.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

Review 4.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

Review 5.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

6.  SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Authors:  Abhishek K Srivastava; Gunes Dinc; Rajesh K Sharma; Esma S Yolcu; Hong Zhao; Haval Shirwan
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

7.  Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model.

Authors:  Xiaoyang Ling; Frank Marini; Marina Konopleva; Wendy Schober; Yuexi Shi; Jared Burks; Karen Clise-Dwyer; Rui-Yu Wang; Weiguo Zhang; Xiaoqing Yuan; Hongbo Lu; Lisa Caldwell; Michael Andreeff
Journal:  Cancer Microenviron       Date:  2010-03-19

8.  Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.

Authors:  Joshua D Brody; Matthew J Goldstein; Debra K Czerwinski; Ronald Levy
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

9.  Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.

Authors:  I Heier; P O Hofgaard; P Brandtzaeg; F L Jahnsen; M Karlsson
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

10.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.